--- title: "Sanofi Strengthens Vaccine and Specialty Care Portfolio With New Nuvaxovid Data and Multiple April 2026 Approvals" type: "News" locale: "en" url: "https://longbridge.com/en/news/284253332.md" description: "Sanofi has announced new phase 4 data for its COVID-19 vaccine Nuvaxovid, showing lower side effects compared to Moderna's mNEXSPIKE, which may enhance its role in vaccination programs from 2026. Additionally, Sanofi revealed U.S. regulatory approvals for Sarclisa, Tzield, and Dupixent, along with a positive CHMP opinion for Cenrifki. These developments highlight Sanofi's expanding presence in immunology, neurology, and diabetes, bolstering its growth profile. Analysts rate SNY stock as a Hold with a $57 price target, while AI analysis suggests an Outperform rating based on financial resilience and earnings outlook." datetime: "2026-04-27T17:19:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284253332.md) - [en](https://longbridge.com/en/news/284253332.md) - [zh-HK](https://longbridge.com/zh-HK/news/284253332.md) --- # Sanofi Strengthens Vaccine and Specialty Care Portfolio With New Nuvaxovid Data and Multiple April 2026 Approvals ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Sanofi ( (SNY) ) just unveiled an update. In April 2026, Sanofi reported new phase 4 data showing its protein‑based, non‑mRNA COVID‑19 vaccine Nuvaxovid had significantly lower systemic and local reactogenicity than Moderna’s latest mRNA shot mNEXSPIKE in a 1,000‑patient, double‑blind U.S. head‑to‑head COMPARE study presented April 18 at the ESCMID Global Congress. With fewer and shorter‑lasting side effects, and recipients more likely to choose it again, the tolerability advantage supports Sanofi’s push to expand Nuvaxovid’s role in routine COVID‑19 vaccination programs from 2026 onward, potentially improving uptake among hesitant adults and reinforcing the company’s competitive position in the post‑pandemic endemic vaccine market. Also in April 2026, Sanofi disclosed that it had issued a series of press releases on U.S. regulatory developments for Sarclisa subcutaneous, new U.S. approvals for Tzield in delaying stage 3 type 1 diabetes in young children and Dupixent in chronic spontaneous urticaria in young children, and a positive CHMP opinion in the EU for Cenrifki (tolebrutinib) in non‑relapsing secondary progressive multiple sclerosis. Together, these late‑stage pipeline milestones and approvals underscore Sanofi’s growing footprint in immunology, neurology and diabetes, strengthening its long‑term growth profile and offering new treatment options for patients with serious chronic and autoimmune conditions. The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page. **Spark’s Take on SNY Stock** According to Spark, TipRanks’ AI Analyst, SNY is a Outperform. The score is driven primarily by solid financial resilience and a constructive earnings outlook (growth, margin expansion, and buybacks). Valuation is supportive with a reasonable P/E and strong dividend, while weaker technical trend signals (below major moving averages and negative MACD) temper the overall rating. To see Spark’s full report on SNY stock, click here. **More about Sanofi** Sanofi is an R&D‑driven, AI‑powered biopharmaceutical company that develops medicines and vaccines, applying its expertise in immunology to treat and protect millions of patients worldwide. Listed on Euronext Paris and Nasdaq, the group focuses on innovative therapies and vaccines across major chronic and infectious diseases, targeting large at‑risk populations and routine immunization markets. **Average Trading Volume:** 4,039,189 **Technical Sentiment Signal:** Sell **Current Market Cap:** $113B Learn more about SNY stock on TipRanks’ Stock Analysis page. ### Related Stocks - [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md) - [SNY.US](https://longbridge.com/en/quote/SNY.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) ## Related News & Research - [Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 | SNY Stock News](https://longbridge.com/en/news/285412645.md) - [18:00 ETZYUS Life Sciences Expands U.S. Patent Portfolio with Second Pain Management Patent](https://longbridge.com/en/news/285274912.md) - [09:37 ETDREAME presenta su línea completa de productos de cuidado personal masculino en Silicon Valley](https://longbridge.com/en/news/285389099.md) - [Abbott’s BurstDR Trial Targets Painful Diabetic Neuropathy: What Investors Should Watch](https://longbridge.com/en/news/285754862.md) - [16:01 ETInnocan Pharma LPT-CBD is featured in Pain Medicine News](https://longbridge.com/en/news/285427579.md)